1临床特点SL占AM L的10%~30%,其中治疗相关性急性髓细胞白血病(t-AM L)约占59%,治疗相关性骨髓增生异常综合征(t-M DS)约占41%。烷化剂所致SL与M DS后的白血病相似,发病前常有白血病前期,三系增生不良,有5、7染色体异常且预后较差;拓扑异构酶Ⅱ抑制剂所致SL患者的潜伏期明显缩 1 Clinical features SL accounts for 10% to 30% of AML, with about 59% of treatment-related acute myeloid leukemia (t-AM L) and about 41% of treatment-associated myelodysplastic syndrome (t-M DS). Alkaloid induced SL and M DS after the leukemia similar to the pre-leukemia often pre-existing, three-line hyperplasia, with 5,7 chromosomal abnormalities and poor prognosis; Topoisomerase Ⅱ inhibitor-induced SL patients with incubation period Significantly reduced